HC Wainwright Issues Pessimistic Estimate for TVTX Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Equities researchers at HC Wainwright cut their FY2025 EPS estimates for Travere Therapeutics in a report released on Monday, December 15th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.68) per share for the year, down from their prior estimate of ($0.56). HC Wainwright currently has a “Buy” rating and a $47.00 target price on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Travere Therapeutics’ Q4 2025 earnings at ($0.31) EPS, FY2026 earnings at $0.54 EPS, FY2027 earnings at $2.09 EPS, FY2028 earnings at $4.09 EPS and FY2029 earnings at $5.13 EPS.

A number of other equities research analysts have also commented on the stock. Jefferies Financial Group set a $35.00 price objective on shares of Travere Therapeutics in a report on Wednesday, September 10th. Cowen reiterated a “buy” rating on shares of Travere Therapeutics in a research report on Friday, October 31st. Stifel Nicolaus increased their price target on shares of Travere Therapeutics from $20.00 to $25.00 and gave the company a “hold” rating in a research note on Friday, September 12th. Wells Fargo & Company raised their price target on shares of Travere Therapeutics from $27.00 to $35.00 and gave the company an “overweight” rating in a report on Thursday, September 11th. Finally, Wall Street Zen upgraded shares of Travere Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Thirteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.71.

Travere Therapeutics Stock Performance

Shares of NASDAQ:TVTX opened at $33.89 on Thursday. The business has a fifty day moving average of $32.61 and a 200-day moving average of $23.28. The company has a debt-to-equity ratio of 4.23, a quick ratio of 2.71 and a current ratio of 2.75. Travere Therapeutics has a twelve month low of $12.91 and a twelve month high of $37.50. The firm has a market cap of $3.03 billion, a PE ratio of -31.97 and a beta of 0.89.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Thursday, October 30th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.59. The firm had revenue of $164.86 million during the quarter, compared to analysts’ expectations of $106.09 million. Travere Therapeutics had a negative return on equity of 178.68% and a negative net margin of 20.32%.The business’s revenue was up 162.1% on a year-over-year basis. During the same period last year, the firm posted ($0.70) EPS.

Institutional Investors Weigh In On Travere Therapeutics

A number of hedge funds have recently modified their holdings of TVTX. Capital Fund Management S.A. bought a new stake in Travere Therapeutics in the 2nd quarter valued at approximately $1,501,000. Squarepoint Ops LLC grew its stake in shares of Travere Therapeutics by 98.7% during the 2nd quarter. Squarepoint Ops LLC now owns 479,394 shares of the company’s stock worth $7,095,000 after acquiring an additional 238,070 shares in the last quarter. Polar Asset Management Partners Inc. acquired a new stake in shares of Travere Therapeutics in the first quarter valued at approximately $304,000. Y Intercept Hong Kong Ltd lifted its position in shares of Travere Therapeutics by 343.7% in the second quarter. Y Intercept Hong Kong Ltd now owns 68,000 shares of the company’s stock worth $1,006,000 after purchasing an additional 52,675 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. bought a new stake in shares of Travere Therapeutics in the second quarter worth $2,486,000.

Insider Activity at Travere Therapeutics

In related news, insider Elizabeth E. Reed sold 10,000 shares of the firm’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the sale, the insider owned 89,878 shares of the company’s stock, valued at approximately $2,246,950. This trade represents a 10.01% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Christopher R. Cline sold 20,000 shares of Travere Therapeutics stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $35.01, for a total value of $700,200.00. Following the transaction, the chief financial officer owned 92,083 shares in the company, valued at approximately $3,223,825.83. This represents a 17.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 243,368 shares of company stock valued at $7,910,972. 4.19% of the stock is owned by corporate insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.